Jiang Qi, Ru Yawei, Yu Yang, Li Keqiu, Jing Yaqing, Wang Jianhai, Li Guang
Department of Basic Medicine, Tianjin Medical College, Tianjin, China; School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Transpl Immunol. 2019 Apr;53:7-12. doi: 10.1016/j.trim.2018.11.005. Epub 2018 Nov 22.
Liver transplantation (LT) is the most effective treatment method for advanced stage liver disease but acute cellular rejection (ACR) seriously affects the prognosis of LT. To discover novel diagnostic biomarkers of ACR after LT, Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-based mass spectrometry was performed to characterize alterations of serum proteins among patients validated to be pathologically ACR or pathologically no-ACR after LT and healthy controls. As a result, 10 differentially expressed proteins were found out between the ACR group and the No-ACR group; 88 differentially expressed proteins were found out between the ACR group and the Healthy Control group; 39 differentially expressed proteins were found out between No-ACR group and Healthy Control group. After analysis and ELISA validation, the results showed that CFHR1, CFHR5 and CFH could be candidate protein biomarkers for the early diagnosis of ACR after LT.
肝移植（LT）是晚期肝病最有效的治疗方法，但急性细胞排斥反应（ACR）严重影响肝移植的预后。为了发现肝移植后ACR的新型诊断生物标志物，采用基于相对和绝对定量等压标签（iTRAQ）的质谱技术，对肝移植后经病理证实为ACR或无ACR的患者及健康对照者血清蛋白的变化进行表征。结果显示，ACR组与无ACR组之间发现10种差异表达蛋白；ACR组与健康对照组之间发现88种差异表达蛋白；无ACR组与健康对照组之间发现39种差异表达蛋白。经过分析和ELISA验证，结果表明CFHR1、CFHR5和CFH可能是肝移植后ACR早期诊断的候选蛋白生物标志物。
